trending Market Intelligence /marketintelligence/en/news-insights/trending/sUpwNfCPF-idwg6DTCKG2A2 content esgSubNav
In This List

Madrigal Pharmaceuticals prices common stock offering

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Madrigal Pharmaceuticals prices common stock offering

Madrigal Pharmaceuticals Inc. priced an underwritten registered public offering of 1,506,025 common shares at $83 apiece.

The company expects gross proceeds of about $125 million.

Madrigal granted underwriters a 30-day option to buy up to an additional 225,904 common shares.

The offering is expected to close by Dec. 21, subject to customary closing conditions.

Goldman Sachs & Co. LLC is acting as lead book-running manager for the offering, with Evercore ISI acting as book runner. JMP Securities, Roth Capital Partners and H.C. Wainwright & Co. are acting as co-managers for the offering.